How I treat juvenile idiopathic arthritis: A state of the art review

Autoimmunity Reviews

Volumn 16, Issue 10, 2017, Pages 1008-1015

  Cimaz, Rolando ^a,b   Marino, Achille ^a,b   Martini, Alberto ^c,d  

^a UNIVERSITY OF FLORENCE   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

^c G GASLINI INSTITUTE   (Italy)

^d UNIVERSITY OF GENOA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ADALIMUMAB; ANAKINRA; BIOLOGICAL PRODUCT; CANAKINUMAB; CERTOLIZUMAB PEGOL; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; RILONACEPT; RITUXIMAB; TOCILIZUMAB; TUMOR NECROSIS FACTOR INHIBITOR;

ABDOMINAL PAIN; AUTOIMMUNE DISEASE; CHILD; DRUG MONITORING; DRUG SAFETY; ENTHESITIS; ENTHESITIS RELATED ARTHRITIS; HUMAN; HYPERTRANSAMINASEMIA; INFECTION; JUVENILE RHEUMATOID ARTHRITIS; MACROPHAGE ACTIVATION SYNDROME; NAUSEA; PRACTICE GUIDELINE; REVIEW; VOMITING;

ARTHRITIS, JUVENILE; CHILD; HUMANS;

EID: 85027241412     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2017.07.014     Document Type: Review

References (120)

1. Ravelli, A., Martini, A., Juvenile idiopathic arthritis. Lancet 369 (2007), 767–778.
2. Maggi, L., Cosmi, L., Simonini, G., Annunziato, F., Cimaz, R., T cell subpopulations in juvenile idiopathic arthritis and their modifications after biotherapies. Autoimmun Rev 15 (2016), 1141–1144.
3. Cimaz, R., Systemic-onset juvenile idiopathic arthritis. Autoimmun Rev 15 (2016), 931–934.
4. Petty, R.E., Southwood, T.R., Manners, P., Baum, J., Glass, D.N., Goldenberg, J., et al. International league of associations for rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 31 (2004), 390–392.
5. Martini, A., It is time to rethink juvenile idiopathic arthritis classification and nomenclature. Ann Rheum Dis 71 (2012), 1437–1439.
6. Lovell, D.J., Ruperto, N., Giannini, E.H., Martini, A., Advances from clinical trials in juvenile idiopathic arthritis. Nat Rev Rheumatol 9 (2013), 557–563.
7. Wallace, C.A., Giannini, E.H., Huang, B., Itert, L., Ruperto, N., Wallace American College of Rheumatology provisional criteria for defining clinical inactive disease in select categories of juvenile idiopathic arthritis. Arthritis Care Res 63 (2011), 929–936.
8. Consolaro, A., Schiappapietra, B., Dalprà, S., Calandra, S., Martini, A., Ravelli, A., Optimisation of disease assessments in juvenile idiopathic arthritis. Clin Exp Rheumatol 32 (2014), 126–130.
9. Smolen, J.S., Aletaha, D., Bijlsma, J.W., Breedveld, F.C., Boumpas, D., Burmester, G., et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum 69 (2010), 631–637.
10. Hissink Muller, P.C.E., Brinkman, D.M.C., Schonenberg, D., Koopman-Keemink, Y., Brederije, I.C.J., Bekkering, W.P., et al. A comparison of three treatment strategies in recent onset non-systemic juvenile idiopathic arthritis: initial 3-months results of the BeSt for Kids-study. Pediatr Rheumatol Online J, 15, 2017, 11.
11. Wallace, C.A., Giannini, E.H., Spalding, S.J., Hashkes, P.J., O'Neil, K.M., Zeft, A.S., et al. Trial of early aggressive therapy in polyarticular juvenile idiopathic arthritis. Arthritis Rheum 64 (2012), 2012–2021.
12. Beukelman, T., Patkar, N.M., Saag, K.G., Tolleson-Rinehart, S., Cron, R.Q., DeWitt, E.M., et al. 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res 63 (2011), 465–482.
13. Ringold, S., Weiss, P.F., Beukelman, T., DeWitt, E.M., Ilowite, N.T., Kimura, Y., et al. 2013 update of the 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: recommendations for the medical therapy of children with systemic juvenile idiopathic arthritis and tuberculosis screening among children receiving biologic medications. Arthritis Rheum 65 (2013), 2499–2512.
14. Ruperto, N., Nikishina, I., Pachanov, E.D., Shachbazian, Y., Prieur, A.M., Mouy, R., et al. A randomized, double-blind clinical trial of two doses of meloxicam compared with naproxen in children with juvenile idiopathic arthritis: short- and long-term efficacy and safety results. Arthritis Rheum 52 (2005), 563–572.
15. Cleary, A.G., Murphy, H.D., Davidson, J.E., Intra-articular corticosteroid injections in juvenile idiopathic arthritis. Arch Dis Child, 88, 2003, 192.
16. Lanni, S., Bertamino, M., Consolaro, A., Pistorio, A., Magni-Manzoni, S., Galasso, R., et al. Outcome and predicting factors of single and multiple intra-articular corticosteroid injections in children with juvenile idiopathic arthritis. Rheumatology 50 (2011), 1627–1634.
17. Zulian, F., Martini, G., Gobber, D., Plebani, M., Zacchello, F., Manners, P., Triamcinolone acetonide and hexacetonide intra-articular treatment of symmetrical joints in juvenile idiopathic arthritis: a double-blind trial. Rheumatology 43 (2004), 1288–1291.
18. Giannini, E.H., Brewer, E.J., Kuzmina, N., Shaikov, A., Maximov, A., Vorontsov, I., et al. Methotrexate in resistant juvenile rheumatoid arthritis. Results of the U.S.A.-U.S.S.R. double-blind, placebo-controlled trial. The pediatric rheumatology collaborative study group and the cooperative children's study group. N Engl J Med 326:16 (1992), 1043–1049.
19. Kremer, J.M., Toward a better understanding of methotrexate. Arthritis Rheum 50 (2004), 1370–1382.
20. Cronstein, B.N., The mechanism of action of methotrexate. Rheum Dis Clin N Am 23 (1997), 739–755.
21. Ruperto, N., Murray, K.J., Gerloni, V., Wulffraat, N., de Oliveira, S.K., Falcini, F., et al. A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate. Arthritis Rheum 50 (2004), 2191–2201.
22. Bartoli, M., Tarò, M., Magni-Manzoni, S., Pistorio, A., Traverso, F., Viola, S., et al. The magnitude of early response to methotrexate therapy predicts long-term outcome of patients with juvenile idiopathic arthritis. Ann Rheum Dis 67 (2008), 370–374.
23. Albers, H.M., Brinkman, D.M., Kamphuis, S.S., van Suijlekom-Smit, L.W., van Rossum, M.A., Hoppenreijs, E.P., et al. Clinical course and prognostic value of disease activity in the first two years in different subtypes of juvenile idiopathic arthritis. Arthritis Care Res 62 (2010), 204–212.
24. Tukova, J., Chladek, J., Nemcova, D., Chladkova, J., Dolezalova, P., Methotrexate bioavailability after oral and subcutaneous administration in children with juvenile idiopathic arthritis. Clin Exp Rheumatol 27 (2009), 1047–1053.
25. Alsufyani, K., Ortiz-Alvarez, O., Cabral, D.A., Tucker, L.B., Petty, R.E., Malleson, P.N., The role of subcutaneous administration of methotrexate in children with juvenile idiopathic arthritis who have failed oral methotrexate. J Rheumatol 31 (2004), 179–182.
26. Hamilton, R.A., Kremer, J.M., Why intramuscular methotrexate may be more efficacious than oral dosing in patients with rheumatoid arthritis. Br J Rheumatol 36 (1997), 86–90.
27. Hoekstra, M., Haagsma, C., Neef, C., Proost, J., Knuif, A., van de Laar, M., Bioavailability of higher dose methotrexate comparing oral and subcutaneous administration in patients with rheumatoid arthritis. J Rheumatol 31 (2004), 645–648.
28. Ravelli, A., Davì, S., Bracciolini, G., Pistorio, A., Consolaro, A., van Dijkhuizen, E.H., et al. Intra-articular corticosteroids versus intra-articular corticosteroids plus methotrexate in oligoarticular juvenile idiopathic arthritis: a multicentre, prospective, randomised, open-label trial. Lancet 389 (2017), 909–916.
29. Gutierrez-Suarez, R., Burgos-Vargas, R., The use of methotrexate in children with rheumatic diseases. Clin Exp Rheumatol 28 (2010), 122–127.
30. Silverman, E., Spiegel, L., Hawkins, D., Petty, R., Goldsmith, D., Schanberg, L., et al. Long-term open-label preliminary study of the safety and efficacy of leflunomide in patients with polyarticular course juvenile rheumatoid arthritis (JRA). Arthritis Rheum 52 (2005), 554–562.
31. Silverman, E., Mouy, R., Spiegel, L., Jung, L.K., Saurenmann, R.K., Lahdenne, P., et al. Leflunomide or methotrexate for juvenile rheumatoid arthritis. N Engl J Med 352 (2005), 1655–1666.
32. Tanaka, T., Kishimoto, T., The biology and medical implications of interleukin-6. Cancer Immunol Res 2 (2014), 288–294.
33. Lovell, D.J., Giannini, E.H., Reiff, A., Cawkwell, G.D., Silverman, E.D., Nocton, J.J., et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric rheumatology collaborative study group. N Engl J Med 342 (2000), 763–769.
34. Quartier, P., Taupin, P., Bourdeaut, F., Lemelle, I., Pillet, P., Bost, M., et al. Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type. Arthritis Rheum 48 (2003), 1093–1101.
35. Horneff, G., Schmeling, H., Biedermann, T., Foeldvari, I., Ganser, G., Girschick, H.J., et al. The German etanercept registry for treatment of juvenile idiopathic arthritis. Ann Rheum Dis 63 (2004), 1638–1644.
36. Giannini, E.H., Ilowite, N.T., Lovell, D.J., Wallace, C.A., Rabinovich, C.E., Reiff, A., et al. Long-term safety and effectiveness of etanercept in children with selected categories of juvenile idiopathic arthritis. Arthritis Rheum 60 (2009), 2794–2804.
37. Southwood, T.R., Foster, H.E., Davidson, J.E., Hyrich, K.L., Cotter, C.B., Wedderburn, L.R., et al. Duration of etanercept treatment and reasons for discontinuation in a cohort of juvenile idiopathic arthritis patients. Rheumatology (Oxford) 50 (2011), 189–195.
38. Horneff, G., De Bock, F., Foeldvari, I., Girschick, H.J., Michels, H., Moebius, D., et al. Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): preliminary data from the German JIA Registry. Ann Rheum Dis 68 (2009), 519–525.
39. Giannini, E.H., Ruperto, N., Ravelli, A., Lovell, D.J., Felson, D.T., Martini, A., Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum 40 (1997), 1202–1209.
40. Verazza, S., Davì, S., Consolaro, A., Bovis, F., Insalaco, A., Magni-manzoni, S., et al. Disease status, reasons for discontinuation and adverse events in 1038 Italian children with juvenile idiopathic arthritis treated with etanercept. Pediatr Rheumatol, 14, 2016, 68.
41. Consolaro, A., Ruperto, N., Bazso, A., Pistorio, A., Magni-Manzoni, S., Filocamo, G., et al. Development and validation of a composite disease activity score for juvenile idiopathic arthritis. Arthritis Rheum 61 (2009), 658–666.
42. Papsdorf, V., Horneff, G., Complete control of disease activity and remission induced by treatment with etanercept in juvenile idiopathic arthritis. Rheumatology (Oxford) 50 (2011), 214–221.
43. Otten, M.H., Prince, F.H., Armbrust, W., ten Cate, R., Hoppenreijs, E.P., Twilt, M., et al. Factors associated with treatment response to etanercept in juvenile idiopathic arthritis. JAMA 306 (2011), 2340–2347.
44. Suryaprasad, A.G., Prindiville, T., The biology of TNF blockade. Autoimmun Rev 2 (2003), 346–357.
45. Nguyen, D.X., Ehrenstein, M.R., Anti-TNF drives regulatory T cell expansion by paradoxically promoting membrane TNF–TNF-RII binding in rheumatoid arthritis. J Exp Med 213 (2016), 1241–1253.
46. Lovell, D.J., Ruperto, N., Goodman, S., Reiff, A., Jung, L., Jarosova, K., et al. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med 359 (2008), 810–820.
47. Schmeling, H., Minden, K., Foeldvari, I., Ganser, G., Hospach, T., Horneff, G., Efficacy and safety of adalimumab as the first and second biologic agent in juvenile idiopathic arthritis: the German Biologics JIA Registry. Arthritis Rheum 66 (2014), 2580–2589.
48. Ruperto, N., Lovell, D.J., Cuttica, R., Wilkinson, N., Woo, P., Espada, G., et al. A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum 56 (2007), 3096–3106.
49. Ruperto, N., Lovell, D.J., Cuttica, R., Woo, P., Meiorin, S., Wouters, C., et al. Long-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis: findings from an open-label treatment extension. Ann Rheum Dis 69 (2010), 718–722.
50. Maggi, L., Cimaz, R., Capone, M., Santarlasci, V., Rossi, M.C., Mazzoni, A., et al. Immunosuppressive activity of abatacept on circulating T helper lymphocytes from juvenile idiopathic arthritis patients. Int Arch Allergy Immunol 171 (2016), 45–53.
51. Ruperto, N., Lovell, D.J., Quartier, P., Paz, E., Rubio-Perez, N., Silva, C.A., et al. Abatacept in children with juvenile idiopathic arthritis: a randomized, double-blind, placebo-controlled withdrawal trial. Lancet 372 (2008), 383–391.
52. Ruperto, N., Lovell, D.J., Quartier, P., Paz, E., Rubio-Perez, N., Silva, C.A., et al. Long-term safety and efficacy of abatacept in children with juvenile idiopathic arthritis. Arthritis Rheum 62 (2010), 1792–1802.
53. Venkiteshwaran, A., Tocilizumab. MAbs 1 (2009), 432–438.
54. Brunner, H.I., Ruperto, N., Zuber, Z., Keane, C., Harari, O., Kenwright, A., et al. Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial. Ann Rheum Dis 74 (2015), 1110–1117.
55. Imagawa, T., Yokota, S., Mori, M., Miyamae, T., Takei, S., Imanaka, H., et al. Safety and efficacy of tocilizumab, an anti-IL-6-receptor monoclonal antibody, in patients with polyarticular-course juvenile idiopathic arthritis. Mod Rheumatol 22 (2012), 109–115.
56. Pagnini, I., Savelli, S., Matucci-Cerinic, M., Fonda, C., Cimaz, R., Simonini, G., Early predictors of juvenile sacroiliitis in enthesitis-related arthritis. J Rheumatol 37 (2010), 2395–2401.
57. Aggarwal, A., Misra, D.P., Enthesitis-related arthritis. Clin Rheumatol 34 (2015), 1839–1846.
58. Huang, J.L., Chen, L.C., Sulphasalazine in the treatment of children with chronic arthritis. Clin Rheumatol 17 (1998), 359–363.
59. Chen, J., Liu, C., Sulfasalazine for ankylosing spondylitis (protocol). Cochrane Database Syst Rev, 3, 2003, CD004800.
60. Horneff, G., Foeldvari, I., Minden, K., Trauzeddel, R., Kuemmerle-Deschner, J., Tenbrock, K., et al. Efficacy and safety of etanercept in patients with the enthesitis-related arthritis category of juvenile idiopathic arthritis. Arthritis Rheum 67 (2015), 2240–2249.
61. Hugle, B., Burgos-Vargas, R., Inman, R.D., O'Shea, F., Laxer, R.M., Stimec, J., et al. Long-term outcome of anti-tumor necrosis factor alpha blockade in the treatment of juvenile spondyloarthritis. Clin Exp Rheumatol 32 (2014), 424–431.
62. Otten, M.H., Prince, F.H.M., Twilt, M., Ten Cate, R., Armbrust, W., Hoppenreijs, E.P., et al. Tumor necrosis factor–blocking agents for children with enthesitis-related arthritis—data from the Dutch Arthritis and Biologicals in Children Register, 1999–2010. J Rheumatol 38 (2011), 2258–2263.
63. Horneff, G., Burgos-Vargas, R., Constantin, T., Foeldvari, I., Vojinovic, J., Chasnyk, V.G., et al. Efficacy and safety of open-label etanercept on extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis and psoriatic arthritis: part 1 (week 12) of the CLIPPER study. Ann Rheum Dis 73 (2014), 1114–1122.
64. Bugos-Vargas, R., Tse, S.M., Horneff, G., Pangan, A.L., Kalabic, J., Goss, S., A randomized, double-blind, placebo-controlled multcenter study of adalimumab in pediatric patients with enthesitis-related arthritis. Arthritis Care Res (Hoboken) 67 (2015), 1503–1512.
65. Cimaz, R., Von Scheven, A., Hofer, M., Systemic-onset juvenile idiopathic arthritis: the changing life of a rare disease. Swiss Med Wkly, 142, 2012, w13582.
66. Woo, P., Southwood, T.R., Prieur, A.M., Dore, C.J., Grainger, J., David, J., et al. Randomized, placebo-controlled, crossover trial of low- dose oral methotrexate in children with extended oligoarticular or systemic arthritis. Arthritis Rheum 43 (2000), 1849–1857.
67. Gattorno, M., Piccini, A., Lasiglie, D., Tassi, S., Brisca, G., Carta, S., et al. The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 58 (2008), 1505–1515.
68. Zeft, A., Hollister, R., LaFleur, B., Sampath, P., Soep, J., McNally, B., et al. Anakinra for systemic juvenile arthritis: the Rocky Mountain experience. J Clin Rheumatol 15 (2009), 161–164.
69. Quartier, P., Allantaz, F., Cimaz, R., Pillet, P., Messiaen, C., Bardin, C., et al. A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANA-JIS trial). Ann Rheum Dis 70 (2011), 747–754.
70. Nigrovic, P.A., Mannion, M., Prince, F.H.M., Zeft, A., Rabinovich, C.E., van Rossum, M.A.J., et al. Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series. Arthritis Rheum 63 (2011), 545–555.
71. Vastert, S.J., de Jager, W., Noordman, B.J., Holzinger, D., Kuis, W., Prakken, B.J., et al. Effectiveness of first-line treatment with recombinant interleukin-1 receptor antagonist in steroid-naive patients with new-onset systemic juvenile idiopathic arthritis: results of a prospective cohort study. Arthritis Rheum 66 (2014), 1034–1043.
72. Hoy, S.M., Canakinumab: a review of its use in the management of systemic juvenile idiopathic arthritis. BioDrugs 29 (2015), 133–142.
73. Ruperto, N., Quartier, P., Wulffraat, N., Woo, P., Ravelli, A., Mouy, R., et al. A phase II study to evaluate dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features. Arthritis Rheum 64 (2012), 557–567.
74. Ruperto, N., Brunner, H.I., Quartier, P., Constantin, T., Wulffraat, N., Horneff, G., et al. Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N Engl J Med 367 (2012), 2396–2406.
75. Brachat, A.H., Grom, A.A., Wulffraat, N., Brunner, H.I., Quartier, P., Brik, R., et al. Early changes in gene expression and inflammatory proteins in systemic juvenile idiopathic arthritis patients on canakinumab therapy. Arthritis Res Ther, 19, 2017, 13.
76. De Benedetti, F., Martini, A., Is systemic juvenile rheumatoid arthritis an interleukin-6 mediated disease?. J Rheumatol 25 (1998), 203–207.
77. Yokota, S., Imagawa, T., Mori, M., Miyamae, T., Aihara, Y., Takei, S., et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet 371 (2008), 998–1006.
78. De Benedetti, F., Brunner, H.I., Ruperto, N., Kenwright, A., Wright, S., Calvo, I., et al. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med 367 (2012), 2385–2395.
79. Machado, S.H., Xavier, R.M., Safety of tocilizumab in the treatment of juvenile idiopathic arthritis. Expert Opin Drug Saf 16 (2017), 493–500.
80. Tarp, S., Amarilyo, G., Foeldvari, I., Christensen, R., Woo, J.M., Cohen, N., et al. Efficacy and safety of biological agents for systemic juvenile idiopathic arthritis: a systematic review and meta-analysis of randomized trials. Rheumatology (Oxford) 55 (2016), 669–679.
81. Minoia, F., Davi, S., Horne, A., Demirkaya, E., Bovis, F., Li, C., et al. Clinical features, treatment, and outcome of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a multinational, multicenter study of 362 patients. Arthritis Rheum 66 (2014), 3160–3169.
82. Ravelli, A., Minoia, F., Davì, S., Horne, A., Bovis, F., Pistorio, A., et al. 2016 classification criteria for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. Ann Rheum Dis 75 (2016), 481–489.
83. Miettunen, P.M., Narendran, A., Jayanthan, A., Behrens, E.M., Cron, R.Q., Successful treatment of severe paediatric rheumatic disease-associated macrophage activation syndrome with interleukin-1 inhibition following conventional immunosuppressive therapy: case series with 12 patients. Rheumatology (Oxford) 50 (2011), 417–419.
84. Grom, A.A., Ilowite, N.T., Pascual, V., Brunner, H.I., Martini, A., Lovell, D., et al. Rate and clinical presentation of macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis treated with canakinumab. Arthritis Rheum 68 (2016), 218–228.
85. Yokota, S., Itoh, Y., Morio, T., Sumitomo, N., Daimaru, K., Minota, S., Macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis under treatment with tocilizumab. J Rheumatol 42 (2015), 712–722.
86. Kearsley-Fleet, L., Davies, R., Baildam, E., Beresford, M.W., Foster, H.E., Southwood, T.R., et al. Factors associated with choice of biologic among children with juvenile idiopathic arthritis: results from two UK paediatric biologic registers. Rheumatology (Oxford) 55 (2016), 1556–1565.
87. Mourão, A.F., Santos, M.J., Melo Gomes, J.A., Martins, F.M., Mendonça, S.C., Oliveira Ramos, et al. effectiveness and long-term retention of anti-tumour necrosis factor treatment in juvenile and adult patients with juvenile idiopathic arthritis: data from Reuma.pt. Rheumatology (Oxford) 55:4 (2016), 697–703.
88. Amarilyo, G., Tarp, S., Foeldvari, I., Cohen, N., Pope, T.D., Woo, J.M., et al. Biological agents in polyarticular juvenile idiopathic arthritis: a meta-analysis of randomized withdrawal trials. Semin Arthritis Rheum 46 (2016), 312–318.
89. Horneff, G., Klein, A., Klotsche, J., Minden, K., Huppertz, H.I., Weller-Heinemann, F., et al. Comparison of treatment response, remission rate and drug adherence in polyarticular juvenile idiopathic arthritis patients treated with etanercept, adalimumab or tocilizumab. Arthritis Res Ther, 18, 2016, 272.
90. Guzman, J., Oen, K., Tucker, L.B., Huber, A.M., Shiff, N., Boire, G., et al. The outcomes of juvenile idiopathic arthritis in children managed with contemporary treatments: results from the ReACCh-Out cohort. Ann Rheum 74 (2015), 1854–1860.
91. Baszis, K., Garbutt, J., Toib, D., Jingnan, M., King, A., White, A., et al. Clinical outcomes after withdrawal of anti–tumor necrosis factor a therapy in patients with juvenile idiopathic arthritis: a twelve-year experience. Arthritis Rheum 63 (2011), 3163–3168.
92. Foell, D., Wulffraat, N., Wedderburn, L.R., Wittkowski, H., Frosch, M., Gerss, J., et al. Methotrexate withdrawal at 6 vs 12 months in juvenile idiopathic arthritis in remission: a randomized clinical trial. JAMA 303 (2010), 1266–1273.
93. Iglesias, E., Torrente-Segarra, V., Bou, R., Ricart, S., Gonzalez, M., Sanchez, J., et al. Non-systemic juvenile idiopathic arthritis after reaching clinical remission with anti-TNFa therapy: a clinical practice observational study of patients who discontinued treatment. Rheumatol Int 33 (2014), 1053–1057.
94. Postepski, J., Kobusinska, K., Olesinska, E., Osinska, V., Opoka-Winiarska, V., Clinical remission in juvenile idiopathic arthritis after termination of etanercept. Rheumatol Int 33 (2013), 2657–2660.
95. Pratsidou-Gertsi, P., Trachana, M., Pardalos, G., Kanakoudi-Tsakalidou, F., A follow-up study of patients with juvenile idiopathic arthritis who discontinued etanercept due to disease remission. Clin Exp Rheumatol 28 (2010), 919–922.
96. Remesal, A., de Inocencio, J., Merino, R., Garcia-Consuegra, J., Discontinuation of etanercept after successful treatment in patients with juvenile idiopathic arthritis. J Rheumatol 37 (2010), 1970–1971.
97. Strey, A., Vogl, T., Wulffraat, N.M., Kuis, W., Sunderkotter, C., et al. Myeloid-related proteins 8 and 14 are specifically secreted during interaction of phagocytes and activated endothelium and are useful markers for monitoring disease activity in pauciarticular-onset juvenile rheumatoid arthritis. Arthritis Rheum 43 (2000), 628–637.
98. Gerss, J., Roth, J., Holzinger, D., Ruperto, N., Wittkowski, H., Frosch, M., et al. Phagocyte-specific S100 proteins and high-sensitivity C reactive protein as biomarkers for a risk-adapted treatment to maintain remission in juvenile idiopathic arthritis: a comparative study. Ann Rheum Dis 71 (2012), 1991–1997.
99. Moncrieffe, H., Ursu, S., Holzinger, D., Patrick, F., Kassoumeri, L., Wade, A., et al. A subgroup of juvenile idiopathic arthritis patients who respond well to methotrexate are identified by the serum biomarker MRP8/14 protein. Rheumatology (Oxford) 52 (2013), 1467–1476.
100. Anink, J., Van Suijlekom-Smit, L.W., Otten, M.H., Prince, F.H., van Rossum, M.A., Dolman, K.M., et al. MRP8/14 serum levels as a predictor of response to starting and stopping anti-TNF treatment in juvenile idiopathic arthritis. Arthritis Res Ther, 17, 2015, 200.
101. Chang, C.Y., Meyer, R.M., Reiff, A.O., Impact of medication withdrawal method on flare-free survival in patients with juvenile idiopathic arthritis on combination therapy. Arthritis Care Res 67 (2015), 658–666.
102. Simonini, G., Scoccimarro, E., Pontikaki, I., Ferrara, G., Giani, T., Taddio, A., et al. Flares after withdrawal of biotherapies in JIA: clinical and laboratory correlates of remission duration [abstract]. Arthritis Rheum, 68(Suppl. 10), 2016.
103. Horton, D.B., Onel, K.B., Beukelman, T., Ringold, S., Attitudes and approaches for withdrawing drugs for children with clinically inactive nonsystemic JIA: a survey of the childhood arthritis and rheumatology research alliance. J Rheumatol 44 (2017), 352–360.
104. Braun, J., Rau, R., An update on methotrexate. Curr Opin Rheumatol 21 (2009), 216–223.
105. Hashkes, P.J., Laxer, R.M., Update on the medical treatment of juvenile idiopathic arthritis. Curr Rheumatol Rep 8 (2006), 450–458.
106. Bulatovic, M., Heijstek, M.W., Van Dijkhuizen, E.H.P., Wulffraat, N.M., Pluijm, S.M.F., de Jonge, R., Prediction of clinical non-response to methotrexate treatment in juvenile idiopathic arthritis. Ann Rheum Dis 71 (2012), 1484–1489.
107. Shea, B., Swinden, M.V., TanjongGhogomu, E., Ortiz, Z., Katchamart, W., Rader, T., et al. Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis. Cochrane Database Syst Rev, 5, 2013, CD000951.
108. Horneff, G., Safety of biologic therapies for the treatment of juvenile idiopathic arthritis. Expert Opin Drug Saf 14 (2015), 1111–1126.
109. Horneff, G., Biologic-associated infections in pediatric rheumatology. Curr Rheumatol Rep, 17, 2015, 66.
110. Camlar, S.A., Makay, B., Appak, O., Appak, Y.C., Esen, N., Günay, T., et al. Performance of tuberculin skin test and interferon gamma assay for the diagnosis of latent tuberculosis infection in juvenile idiopathic arthritis. Clin Rheumatol 30 (2011), 1189–1193.
111. Marino, A., Chiappini, E., Cimaz, R., Simonini, G., Prebiologic therapy tuberculosis screening experience in a pediatric rheumatology center: TST and IGRA are both necessary. Pediatr Infect Dis J 36 (2017), 440–441.
112. Kosmač, M., Avčin, T., Toplak, N., Simonini, G., Cimaz, R., CurinŠerbec, V., Exploring the binding sites of anti-infliximab antibodies in pediatric patients with rheumatic diseases treated with infliximab. Pediatr Res 69 (2011), 243–248.
113. Skrabl-Baumgartner, A., Erwa, W., Muntean, W., Jahnel, J., Anti-adalimumab antibodies in juvenile idiopathic arthritis: frequent association with loss of response. Scand J Rheumatol 44 (2015), 359–362.
114. Paine, A., Ritchlin, C.T., Targeting the interleukin-23/17 axis in axial spondyloarthritis. Curr Opin Rheumatol 28 (2016), 359–367.
115. Poddubnyy, D., Hermann, K.G., Callhoff, J., Listing, J., Sieper, J., Ustekinumab for the treatment of patients with active ankylosing spondylitis: results of a 28-week, prospective, open-label, proof-of- concept study (TOPAS). Ann Rheum Dis 73 (2014), 817–823.
116. Baeten, D., Baraliakos, X., Braun, J., Sieper, J., Emery, P., van der Heijde, D., et al. Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial. Lancet 382 (2013), 1705–1713.
117. Ilowite, N.T., Prather, K., Lokhnygina, Y., Schanberg, L.E., Elder, M., Milojevic, D., et al. Randomized, double-blind, placebo-controlled trial of the efficacy and safety of rilonacept in the treatment of systemic juvenile idiopathic arthritis. Arthritis Rheum 66 (2014), 2570–2579.
118. Lovell, D.J., Giannini, E.H., Reiff, A.O., Kimura, Y., Li, S., Hashkes, P.J., et al. Long-term safety and efficacy of rilonacept in patients with systemic juvenile idiopathic arthritis. Arthritis Rheum 65 (2013), 2486–2496.
119. Lopez-Olivo, M.A., AmezagaUrruela, M., McGahan, L., Pollono, E.N., Suarez-Almazor, M.E., Rituximab for rheumatoid arthritis. Cochrane Database Syst Rev, 2015, CD007356.
120. Ruperto, N., Martini, A., International research networks in pediatric rheumatology: the PRINTO perspective. Curr Opin Rheumatol 16 (2004), 566–570.